title: Synthesis and antimuscarinic properties of some N-substituted 5-(aminomethyl)-3,3-diphenyl-2(3H)-furanones.
abstract: In a study aimed toward developing new, selective antimuscarinic drugs with potential utility in the treatment of urinary incontinence associated with bladder muscle instability, a series of N-substituted 5-(aminomethyl)-3,3-diphenyl-2(3H)-furanones, conformationally-constrained lactone relatives of benactyzine, was prepared. The compounds were examined in several paradigms that measure muscarinic (M1, M2, and M3) receptor antagonist activity. Selected members of the series that displayed potency and/or selectivity in these tests were studied for their effects on urinary bladder contraction, mydriasis, and salivation in guinea pigs. These studies revealed that incorporation of the amino functionality into an imidazole or pyrazole ring resulted in some novel, potent, and selective antimuscarinic agents. Appropriate alkyl substitution of position 2 of the imidazole strikingly affected muscarinic, particularly M3, receptor activity and may reflect a complementary site of interaction. Some of the compounds selectively reduced bladder pressure in a cystometrogram (CMG) model without producing concomitant mydriatic and salivary effects. The separate and distinct action of several compounds of this series in these in vivo protocols suggests the possibility of subtypes of muscarinic receptors that may correspond to previously characterized molecular cloned subpopulations. In this article, structure-activity relationships for the series of substituted lactones are discussed. These studies led to the identification of (R)-[(2-isopropyl-1H-imidazol-1-yl)methyl]-4,5-dihydro-3,3-diphenyl-2(3H )- furanone (23) as a clinical candidate for treating urinary bladder dysfunction.
authors.affiliation: Scios Nova Inc., Baltimore, Maryland 21224-6522.
authors.forename: C
authors.initials: C
authors.lastname: Kaiser
authors.forename: C J
authors.initials: CJ
authors.lastname: Spagnuolo
authors.forename: T C
authors.initials: TC
authors.lastname: Adams
authors.forename: V H
authors.initials: VH
authors.lastname: Audia
authors.forename: A C
authors.initials: AC
authors.lastname: Dupont
authors.forename: H
authors.initials: H
authors.lastname: Hatoum
authors.forename: V C
authors.initials: VC
authors.lastname: Lowe
authors.forename: J C
authors.initials: JC
authors.lastname: Prosser
authors.forename: B L
authors.initials: BL
authors.lastname: Sturm
authors.forename: L
authors.initials: L
authors.lastname: Noronha-Blob
mesh_terms: D000818:Animals; D005663:Furans / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D006168:Guinea Pigs; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D010276:Parasympatholytics / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D011817:Rabbits; D011976:Receptors, Muscarinic / Q000187:drug effects; D013329:Structure-Activity Relationship
chemical_list: D005663:Furans; D010276:Parasympatholytics; D011976:Receptors, Muscarinic